Regeneron Pharmaceuticals, Inc. Insider Trading

REGN

Last 12 months

Insiders sold $47.2M and bought nothing on the open market.

31% of the selling was scheduled in advance under 10b5-1 plans. Director George L Sing sold $20.4M on Nov 2, 44% of their stake, outside a plan. The last open-market buy by an executive or director was in Nov 2014.

Net open-market

−$47.2M

0 buys · 21 sales

Under a 10b5-1 plan

31%

of the value sold

Insiders who bought / sold

0 / 11

executives and directors

Last open-market buy

Nov 2014

Nov 25, 2014

Get an email when REGN's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Nov 2	George L Sing Director	SoldNo plan 9 parts	21,129	$964.38 average	$20.4M	44%	Form 4
Nov 2	Christine A Poon Director	SoldNo plan 6 parts	7,830	$969.09 average	$7.59M	60%	Form 4
Nov 2	Joseph J Larosa EVP General Counsel and Secret	SoldNo plan 2 parts	4,466	$965.49 average	$4.31M	9.1%	Form 4
Oct 30	Kathryn Guarini Director	Sold10b5-1 plan	400	$900.00	360K	40%	Form 4
Oct 30	Michael S Brown Director	Sold10b5-1 plan	1,929	$875.00	$1.69M	13%	Form 4
Oct 30	Marion McCourt EVP Commercial	Sold10b5-1 plan	1,132	$869.43	984K	9.3%	Form 4
Oct 14	Andrew J Murphy Co-Chief Scientific Officer	Sold10b5-1 plan 27 parts	4,147	$772.70 average	$3.2M	7.4%	Form 4
Sep 2 – 3	Marion McCourt EVP Commercial	Sold10b5-1 plan 2 parts	2,346	$853.56 average	$2M	16%	Form 4
Sep 2	Kathryn Guarini Director	Sold10b5-1 plan	400	$850.00	340K	40%	Form 4
Aug 10	Kathryn Guarini Director	Sold10b5-1 plan	400	$800.00	320K	40%	Form 4
Aug 10	Huda Y Zoghbi Director	Sold10b5-1 plan	800	$800.00	640K	32%	Form 4
Jul 2	Arthur F Ryan Director	Sold10b5-1 plan	200	$650.15	130K	1.1%	Form 4
May 1	Arthur F Ryan Director	Sold10b5-1 plan 12 parts	100	$705.24 average	71K	0.6%	Form 4
Apr 1	Arthur F Ryan Director	Sold10b5-1 plan 9 parts	100	$777.27 average	78K	0.6%	Form 4
Mar 2	Arthur F Ryan Director	Sold10b5-1 plan 13 parts	100	$785.50 average	79K	0.6%	Form 4
Feb 19	Huda Y Zoghbi Director	Sold10b5-1 plan 11 parts	1,638	$781.33 average	$1.28M	49%	Form 4
Feb 9	Jason Pitofsky SVP Controller	Sold10b5-1 plan 11 parts	2,036	$778.52 average	$1.59M	31%	Form 4
Feb 9	Arthur F Ryan Director	Sold10b5-1 plan 13 parts	100	$778.53 average	78K	0.6%	Form 4
Jan 7	Bonnie L Bassler Director	Sold10b5-1 plan	1,500	$800.00	$1.2M	47%	Form 4
Nov 20, 2025	Bonnie L Bassler Director	Sold10b5-1 plan	760	$750.00	570K	33%	Form 4
Nov 7, 2025	Jason Pitofsky VP Controller	SoldNo plan	431	$651.43	281K	8.8%	Form 4
Oct 29, 2025	Christine A Poon Director	SoldNo plan 6 parts	6,500	$654.27 average	$4.25M	56%	Form 4

Nov 2No plan
George L Sing
Director · sold 21,129 at avg $964.38
$20.4M
44% of stake
Nov 2No plan
Christine A Poon
Director · sold 7,830 at avg $969.09
$7.59M
60% of stake
Nov 2No plan
Joseph J Larosa
EVP General Counsel and Secret · sold 4,466 at avg $965.49
$4.31M
9.1% of stake
Oct 3010b5-1 plan
Kathryn Guarini
Director · sold 400 at $900.00
360K
40% of stake
Oct 3010b5-1 plan
Michael S Brown
Director · sold 1,929 at $875.00
$1.69M
13% of stake
Oct 3010b5-1 plan
Marion McCourt
EVP Commercial · sold 1,132 at $869.43
984K
9.3% of stake
Oct 1410b5-1 plan
Andrew J Murphy
Co-Chief Scientific Officer · sold 4,147 at avg $772.70
$3.2M
7.4% of stake
Sep 2 – 310b5-1 plan
Marion McCourt
EVP Commercial · sold 2,346 at avg $853.56
$2M
16% of stake
Sep 210b5-1 plan
Kathryn Guarini
Director · sold 400 at $850.00
340K
40% of stake
Aug 1010b5-1 plan
Kathryn Guarini
Director · sold 400 at $800.00
320K
40% of stake
Aug 1010b5-1 plan
Huda Y Zoghbi
Director · sold 800 at $800.00
640K
32% of stake
Jul 210b5-1 plan
Arthur F Ryan
Director · sold 200 at $650.15
130K
1.1% of stake
May 110b5-1 plan
Arthur F Ryan
Director · sold 100 at avg $705.24
71K
0.6% of stake
Apr 110b5-1 plan
Arthur F Ryan
Director · sold 100 at avg $777.27
78K
0.6% of stake
Mar 210b5-1 plan
Arthur F Ryan
Director · sold 100 at avg $785.50
79K
0.6% of stake
Feb 1910b5-1 plan
Huda Y Zoghbi
Director · sold 1,638 at avg $781.33
$1.28M
49% of stake
Feb 910b5-1 plan
Jason Pitofsky
SVP Controller · sold 2,036 at avg $778.52
$1.59M
31% of stake
Feb 910b5-1 plan
Arthur F Ryan
Director · sold 100 at avg $778.53
78K
0.6% of stake
Jan 710b5-1 plan
Bonnie L Bassler
Director · sold 1,500 at $800.00
$1.2M
47% of stake
Nov 20, 202510b5-1 plan
Bonnie L Bassler
Director · sold 760 at $750.00
570K
33% of stake
Nov 7, 2025No plan
Jason Pitofsky
VP Controller · sold 431 at $651.43
281K
8.8% of stake
Oct 29, 2025No plan
Christine A Poon
Director · sold 6,500 at avg $654.27
$4.25M
56% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch REGN, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with REGN

CompareIntrinsic value

TEVATeva Pharmaceutical Industries Ltd

$42.13+0.52%46

UPCUniverse Pharmaceuticals Inc.

$1.47-1.34%39

VTRSViatris Inc.

$19.22+1.59%24

VRTXVertex Pharmaceuticals Incorporated

$549.04+3.44%47

BHCBausch Health Companies Inc.

$8.34+2.46%56

ZTSZoetis Inc.

$89.21+7.49%79

ONCBeOne Medicines Ltd.

$377.78+6.42%65

OGNOrganon & Co.

$13.83-0.14%28

Held by ETFs

REGN is in 366 US ETFs. The largest of them, with REGN's weight in each:

Spot a number that looks wrong? Check it in REGN's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing REGN

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.